Related Experiment Video
Updated: Aug 8, 2026
Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix
Published on: October 20, 2021
Direct ex vivo analysis of dendritic cells in patients with hepatocellular carcinoma
Lars-A Ormandy1, Anatol Farber, Tobias Cantz
1Department of Gastroenterology, Hepatology und Endocrinology, Medizinische Hochschule Hannover, Carl Neuberg Str. 1, 30625 Hannover, Germany.
Insights
Hepatocellular carcinoma (HCC) patients have reduced myeloid dendritic cells (mDCs). These mDCs show impaired IL-12 secretion, potentially hindering anti-tumor immune responses and suggesting IL-12 therapies for HCC treatment.
Area of Science:
- Immunology
- Oncology
- Cell Biology
Background:
- Dendritic cells (DCs) are crucial for initiating adaptive immune responses.
- Hepatocellular carcinoma (HCC) is a major global health concern with complex immune interactions.
- Understanding DC function in HCC is vital for developing effective immunotherapies.
Purpose of the Study:
- To investigate the phenotype and function of myeloid dendritic cells (mDCs) in patients with hepatocellular carcinoma (HCC).
- To elucidate the role of mDCs in the immune landscape of HCC.
Main Methods:
- Enumeration of peripheral blood mDCs in HCC patients and healthy controls.
- Analysis of mDC surface marker expression (CD80, CD83, CD86, HLA-DR).
- Functional assays including phagocytosis, peptide-specific T cell stimulation, allogeneic T cell stimulation, and cytokine secretion (IL-12).
Main Results:
- A significant reduction in mDC numbers was observed in HCC patients compared to controls.
- No significant differences in the expression of key surface markers on naive or stimulated mDCs.
- While phagocytosis and peptide-specific T cell stimulation were normal, mDCs from HCC patients exhibited impaired allogeneic T cell stimulatory capacity and reduced IL-12 secretion.
Conclusions:
- Reduced IL-12 production by mDCs in HCC patients may contribute to impaired T cell activation.
- This dysfunction suggests a potential mechanism for immune evasion in HCC.
- Targeting IL-12 pathways could represent a promising therapeutic strategy to enhance anti-tumor immunity in HCC.
Aim:
To analyze the phenotype and function of dendritic cells (DC) from patients with hepatocellular carcinoma (HCC) in order to understand their role in this disease.
Methods:
Myeloid dendritic cells were enumerated in peripheral blood of HCC patients. CD80, CD83, CD86 and HLA-DR expression on naive and stimulated myeloid dendritic cells from peripheral blood were analyzed. Myeloid dendritic cells were isolated from peripheral blood and their function was tested. Phagocytosis was analyzed using FITC-dextran beads, peptide specific stimulation, the capacity to stimulate allogeneic T cells and secretion of cytokines upon poly dI:dC was tested.
Results:
Myeloid dendritic cells were reduced in patients with HCC. No differences in CD80, CD83, CD86 and HLA-DR expression were found on naive and stimulated myeloid dendritic cells from HCC patients and healthy controls. Normal phagocytosis or stimulation of peptide specific T cells was observed in contrast to an impaired allo-stimulatory capacity and a reduced IL-12 secretion.
Conclusion:
Impaired IL-12 production of mDCs in patients could lead to an impaired stimulatory capacity of naive T cells suggesting that IL-12 directed therapies may enhance tumor specific immune responses in HCC patients.
More Related Videos
08:25Mass Cytometry Analysis of Systemic and Local Immune Responses in Hepatocellular Carcinoma
Published on: April 25, 2025
07:32Mast Cells in the Microenvironment of Hepatocellular Carcinoma Confer Favorable Prognosis: A Retrospective Study using QuPath Image Analysis Software
Published on: April 12, 2024